Free Trial
NASDAQ:UTHR

United Therapeutics (UTHR) Stock Price, News & Analysis

United Therapeutics logo
$591.17 -2.14 (-0.36%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$591.25 +0.08 (+0.01%)
As of 11/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About United Therapeutics Stock (NASDAQ:UTHR)

Advanced

Key Stats

Today's Range
$587.00
▼
$598.84
50-Day Range
$472.21
▼
$608.49
52-Week Range
$455.63
▼
$614.23
Volume
463,506 shs
Average Volume
537,533 shs
Market Capitalization
$25.18 billion
P/E Ratio
22.31
Dividend Yield
N/A
Price Target
$676.40
Consensus Rating
Moderate Buy

Company Overview

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma.

Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs. Its research includes organ manufacturing approaches such as 3D bioprinting and the development of organs for transplantation.

Headquartered in Silver Spring, Maryland, the company serves patients in the United States and in selected international markets. Rothblatt remains the company’s chair and chief executive officer.

AI Generated. May Contain Errors.

United Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
93rd Percentile Overall Score

UTHR MarketRank™: 
4.65725541694 of 5 stars

United Therapeutics scored higher than 93% of companies evaluated by MarketBeat, and ranked 19th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    United Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on no strong buy ratings, 12 buy ratings, 3 hold ratings, and 1 sell rating.

  • Upside Potential

    United Therapeutics has a consensus price target of $676.40, representing about 14.4% upside from its current price of $591.17.

  • Amount of Analyst Coverage

    United Therapeutics has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about United Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for United Therapeutics are expected to grow by 27.79% in the coming year, from $25.08 to $32.05 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of United Therapeutics is 22.31, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.40.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of United Therapeutics is 22.31, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.56.

  • Price to Earnings Growth Ratio

    United Therapeutics has a PEG Ratio of 3.94. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    United Therapeutics has a P/B Ratio of 4.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.72% of the float of United Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    United Therapeutics has a short interest ratio ("days to cover") of 3.45, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in United Therapeutics has recently decreased by 25.23%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    United Therapeutics does not currently pay a dividend.

  • Dividend Growth

    United Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    United Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 29 news articles for United Therapeutics this week, compared to 12 articles on an average week.
  • Search Interest

    Only 11 people have searched for UTHR on MarketBeat in the last 30 days. This is a decrease of -15% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added United Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, United Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $220,975,006.00 in company stock.

  • Percentage Held by Insiders

    8.60% of the stock of United Therapeutics is held by insiders.

  • Percentage Held by Institutions

    94.08% of the stock of United Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about United Therapeutics' insider trading history.
Receive UTHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

UTHR Stock News Headlines

FY2026 Earnings Forecast for UTHR Issued By HC Wainwright
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
HC Wainwright Initiates Coverage on United Therapeutics (NASDAQ:UTHR)
See More Headlines

UTHR Stock Analysis - Frequently Asked Questions

United Therapeutics' stock was trading at $487.25 at the beginning of the year. Since then, UTHR stock has increased by 21.3% and is now trading at $591.17.

United Therapeutics Corporation (NASDAQ:UTHR) issued its quarterly earnings data on Wednesday, November, 4th. The biotechnology company reported $5.71 EPS for the quarter, missing the consensus estimate of $6.01 by $0.30. The firm's quarterly revenue was up 4.1% on a year-over-year basis.
Read the conference call transcript
.

United Therapeutics' board authorized a share repurchase program on Thursday, October 22nd 2026, which authorizes the company to buy back $2 billion in outstanding shares, according to EventVestor. This means that the company could purchase up to 8.3% of its shares through open market purchases. Shares buyback programs are usually a sign that the company's board believes its shares are undervalued.

United Therapeutics' top institutional shareholders include State Street Corp (4.58%), First Trust Advisors LP (0.82%), Pictet Asset Management Holding SA (0.55%) and Fifth Third Bancorp (0.35%). Insiders that own company stock include Martine A Rothblatt, Paul A Mahon, Richard Giltner, James Edgemond, Ray Kurzweil, Tommy G Thompson, Nilda Mesa, Judy D Olian, Christopher Causey, Christopher Patusky, Raymond Dwek, Jan Malcolm, Michael Benkowitz and Louis W Sullivan.
View institutional ownership trends
.

Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that United Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Broadcom (AVGO), Bristol Myers Squibb (BMY), Regeneron Pharmaceuticals (REGN), Gilead Sciences (GILD) and Micron Technology (MU).

Company Calendar

Last Earnings
11/04/2026
Today
11/15/2026
UBS Global Biopharma Conference 2026
11/16/2026
Jefferies Global Healthcare Conference
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:UTHR
CIK
1082554
Employees
1,400
Year Founded
1996

Price Target and Rating

High Price Target
$850.00
Low Price Target
$368.00
Potential Upside/Downside
+14.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.69
Research Coverage
16 Analysts

Profitability

EPS (Trailing Twelve Months)
$26.50
Trailing P/E Ratio
22.31
Forward P/E Ratio
18.45
P/E Growth
3.94
Net Income
$1.33 billion
Net Margins
38.61%
Pretax Margin
47.30%
Return on Equity
19.18%
Return on Assets
17.07%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.61
Quick Ratio
4.29

Sales & Book Value

Annual Sales
$3.19 billion
Price / Sales
7.90
Cash Flow
$32.86 per share
Price / Cash Flow
17.99
Book Value
$147.36 per share
Price / Book
4.01

Miscellaneous

Outstanding Shares
42,589,000
Free Float
38,926,000
Market Cap
$25.18 billion
Optionable
Optionable
Beta
0.49

Social Links

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NASDAQ:UTHR) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners